Market research
SAR.LSE Sareum Holdings plc
LSE GBP Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 38M
- P/E ratio
- Not available
- Analyst target
- 41.6
- Dividend yield
- Not available
- Beta
- -0.56
Profile
Instrument facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BMC3RJ87
- Market cap
- 38M
- P/E ratio
- Not available
- Analyst target
- 41.6
- Dividend yield
- Not available
- Beta
- -0.56
About
About Sareum Holdings plc
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Chk 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company has strategic collaboration with Receptor.AI launched in August 2025 to accelerate discovery and optimisation of BBB-permeable TYK2/JAK1 inhibitors; and completion of initial stage expected Q4 2025. Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.
Research context
Sareum Holdings plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SAR.LSE discussion.
5 years, 6 months ago
Sareum Holdings plc is currently in a long term uptrend where the price is trading 195.2% above its 200 day moving average.
From a valuation standpoint, the stock is 149.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1109.3.
Based on the above factors, Sareum Holdings plc gets an overall score of 1/5.